Multi-centre Observational Study to Evaluate the Clinical Utility of Returning Genomic Aberration Results Using the Oncomine Precision Assay (OPA) in Advanced or Metastatic NSCLC within the Exactis Network

exactis

The Exactis-01 trial, a PMT sub-study “Multi-centre Observational Study to Evaluate the Clinical Utility of Returning Genomic Aberration Results Using the Oncomine Precision Assay (OPA) in Advanced or Metastatic NSCLC within the Exactis Network” will be open at several PMT sites and Princess Margaret Hospital, the PI of the study is Dr. Jason Agulnik from the Jewish General Hospital.

The main objective is to demonstrate the non-inferiority of the OPA vs. SOC. Blood and/or tissue will be profiled for up to 200 patients at Exactis’ Network Laboratory George Dumont Hospital in Moncton, and results will be returned to the treating oncologist. Blood samples of patients who received targeted or immune therapy will be profiled at progression.

Results will inform on clinical utility of liquid biopsies, treatment trajectory, access to clinical trials, and tumor evolution. Study also includes exploratory analysis of extracellular vesicles total nucleic acids by Dr. Rodney Ouelette. We anticipate study start in Fall 2020.